Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.

Article  CAS  PubMed  Google Scholar 

Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000–9.

Article  PubMed  Google Scholar 

Goel R, Danda D, Joseph G, Ravindran R, Kumar S, Jayaseelan V, et al. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in Southern India. Semin Arthritis Rheum. 2018;47(5):718–26.

Article  CAS  PubMed  Google Scholar 

Seko Y, Takahashi N, Tada Y, Yagita H, Okumura K, Nagai R. Restricted usage of T-cell receptor Vgamma-Vdelta genes and expression of costimulatory molecules in Takayasu’s arteritis. Int J Cardiol. 2000;75(Suppl 1):S77-83.

Article  PubMed  Google Scholar 

Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev. 2011;11(1):61–7.

Article  CAS  PubMed  Google Scholar 

Misra DP, Chaurasia S, Misra R. Increased circulating Th17 cells, serum IL-17A, and IL-23 in Takayasu arteritis. Autoimmune Dis. 2016;2016:7841718.

PubMed  PubMed Central  Google Scholar 

Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353–60.

Deng J, Ma-Krupa W, Gewirtz AT, Younge BR, Goronzy JJ, Weyand CM. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res. 2009;104(4):488–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nistala K, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci. 2010;107(33):14751–6.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Krausgruber T, Redl A, Barreca D, Doberer K, Romanovskaia D, Dobnikar L, et al. Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. Immunity. 2023;56(2):289-306.e7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, et al. IFN-γ-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan NW, Wang S, Ortiz G, Chauhan SK, Chen Y, Dana R. Autoreactive memory Th17 cells are principally derived from T-bet+RORγt+ Th17/1 effectors. J Autoimmun. 2022;129:102816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi T, Dejbakhsh-Jones S, Strober S. (2006) Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol Baltim Md. 1950;176(1):211–6.

Google Scholar 

Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211(1):89–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.

Article  CAS  PubMed  Google Scholar 

Maeda S, Osaga S, Maeda T, Takeda N, Tamechika S, Naniwa T, et al. Circulating Th171 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: an exploratory research. PLOS ONE. 2019;14(11):e0215192.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goel R, Nair A, Kabeerdoss J, Mohan H, Jeyaseelan V, Joseph G, et al. Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study. Rheumatol Int. 2018;38(4):623–30.

Article  CAS  PubMed  Google Scholar 

García-Carrasco M, Mendoza-Pinto C, Macias Díaz S, Vera-Recabarren M, Vázquez de Lara L, Méndez Martínez S, et al. P-glycoprotein in autoimmune rheumatic diseases. Autoimmun Rev. 2015;7:594–600.

Article  Google Scholar 

Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Argüelles A, Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine. 2000;67(1):40–8.

CAS  PubMed  Google Scholar 

Llorente L, Richaud-Patin Y, Díaz-Borjón A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine. 2000;67(1):30–9.

CAS  PubMed  Google Scholar 

Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol. 2012;16(1):102–8.

Article  CAS  PubMed  Google Scholar 

Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, et al. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017;129(6):740–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fearfield LA, Ross JR, Farrell AM, Costello C, Bunker CB, Staughton RC. Pyoderma gangrenosum associated with Takayasu’s arteritis responding to cyclosporin. Br J Dermatol. 1999;141(2):339–43.

Article  CAS  PubMed  Google Scholar 

Shimizu M, Ueno K, Ishikawa S, Tokuhisa Y, Inoue N, Yachie A. Successful multitarget therapy using mizoribine and tacrolimus for refractory Takayasu arteritis. Rheumatol Oxf Engl. 2014;53(8):1530–2.

Article  Google Scholar 

Fergusson JR, Fleming VM, Klenerman P. CD161-Expressing human T cells. Front Immunol [Internet]. 2011 Aug 30 [cited 2021 Feb 17];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342360/

Basdeo SA, Moran B, Cluxton D, Canavan M, McCormick J, Connolly M, et al. Polyfunctional, pathogenic CD161+ Th17 lineage cells are resistant to regulatory T cell-mediated suppression in the context of autoimmunity. J Immunol. 2015;195(2):528–40.

Article  CAS  PubMed  Google Scholar 

Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64(11):3788–98.

Article  CAS  PubMed  Google Scholar 

Li L, He J, Zhu L, Yang Y, Jin Y, Jia R, et al. The clinical relevance of IL-17-producing CD4+CD161+ cell and its subpopulations in primary Sjögren’s syndrome. J Immunol Res. 2015;2015:307453.

Article  PubMed  PubMed Central  Google Scholar